Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

NCT01054300 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Adult

Interventions

DRUG: Ertugliflozin 2 mg single dose
DRUG: Ertugliflozin 2 mg split into twice daily
DRUG: Ertugliflozin 4 mg single dose
DRUG: Ertugliflozin 4 mg split into twice daily
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]